Cristina Nadal, Executive Director of Government Affairs at MSD Spain, appointed new President of the Spanish Bioindustry Association

Cristina Nadal, Executive Director of Government Affairs at MSD Spain, has been elected President of the Spanish Bioindustry Association (AseBio) at the Ordinary and Extraordinary General Assembly held this Thursday, December 18, 2025, in Madrid. AseBio members also elected the new Vice Presidents: Rocío Arroyo, CEO of Amadix (First Vice President); Santiago de Torres, President of Atrys Health (Second Vice President); and Carlota Gómez de la Hoz, Executive Director of Corporate Affairs and Sustainability at Hipra (Third Vice President).

The new AseBio presidency places a clear ambition at the center: to transform Spain’s growth model in order to drive a more competitive economy that improves people’s lives and contributes to the sustainability of the planet. This vision is underpinned by strengthening and expanding the Spanish biotechnology ecosystem, promoting sustainable growth and cutting-edge health.

The program is committed to an Association that connects its members with one another and with the broader ecosystem, shares knowledge, supports the development of new initiatives, and firmly represents the voice of the sector before public authorities. To this end, the strategic priorities focus on improving and protecting citizens’ quality of life; driving the sustainable transformation of the agri-food and industrial system; reinforcing the strategic and geopolitical position of biotechnology; bringing the Association closer to society; and promoting the internationalization of the sector to increase its global reach and impact.

“Taking on the presidency of AseBio alongside three professionals and companies that are benchmarks for Spanish and global biotechnology is both an honor and a responsibility that I embrace with enthusiasm and commitment. Today, more than ever, we need a united, connected sector prepared to face the challenges of a changing world. It is time to promote a biotechnology that is present in public and strategic conversations, creating the conditions that allow our companies and research centers to innovate and grow. This is a time that demands vision and perspective, but also commitment and collaboration. Together, with shared ambition, we will strengthen Spanish biotechnology and project its value within and beyond our borders,” said the new President of AseBio, Cristina Nadal.

The AseBio General Assembly also elected eight members of its Board of Directors:

• Antonio López (Science & Innovation Link Office)
• Carles Doménech (Ability Pharmaceuticals)
• Carlos Buesa Arjol (Oryzon Genomics)
• Elena Erroba Esquiroz (3P BIOVIAN)
• Elena Rivas (Bionido Capital)
• Jordi Arnalte Olloguegui (Bayer Hispania)
• Laura Pellisé (Amgen)
• Montserrat Vendrell (Asabys Partners)